Start-up Ra Pharma Emerges from Stealth, Targeting HAE
Four years after its launch and two years after the company quietly secured a $27 million Series A round, Ra Pharmaceuticals Inc. revealed hereditary angioedema (HAE) as the initial target for its cyclomimetics – peptide-like molecules that incorporate non-natural amino acids.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter